Document is current
Any future updates will be listed below
-
Authors
Krijnen, Eva A. https://orcid.org/0000-0002-3628-4127
Broeders, Tommy A. A.
Noteboom, Samantha
van Dam, Maureen
Bajrami, Albulena
Bouman, Piet M.
Barkhof, Frederik
Uitdehaag, Bernard M. J.
Klawiter, Eric C.
Koubiyr, Ismail
Schoonheim, Menno M.
-
Funding
Funding for this research was provided by:
ZonMW (09150172010056)
- License Information
-
More Information
Article History
Received: 8 December 2023
Revised: 1 February 2024
Accepted: 5 February 2024
First Online: 5 March 2024
Declarations
:
: EAK, TAAB, and AB report no conflicts of interest; SN is supported by research grants from Atara Biotherapeutics, Merck and Biogen; MvD is supported by a research grant from BMS. PMB received research support from the Dutch MS Research Foundation; FB is a steering committee or iDMC member for Biogen, Merck, Roche, EISAI, Prothena, is a consultant to Roche, Biogen, Merck, IXICO, Jansen, Combinostics, has research agreements with Novartis, Merck, Biogen, GE Healthcare, and Roche, and is co-founder & shareholder of Queen Square Analytics LTD; BMJU reports research support and/or consultancy fees from Biogen Idec, Genzyme, Merck Serono, Novartis, Roche, Teva, and Immunic Therapeutics; ECK has received consulting fees from EMD Serono, Genentech, INmune Bio, Myrobalan Therapeutics, OM1and TG Therapeutics, and received research funds from Abbvie, Biogen, and Genentech; IK received research grants from LabEx TRAIL and ARSEP and speakers’ honoraria from Celgene; MMS serves on the editorial board of Neurology and Frontiers in Neurology and Multiple Sclerosis Journal, receives research support from the Dutch MS Research Foundation, Eurostars-EUREKA, ARSEP, Amsterdam Neuroscience, MAGNIMS and ZonMW and has served as a consultant for or received research support from EIP Pharma, Atara Biotherapeutics, Biogen, Celgene/Bristol Meyers Squibb, Genzyme, MedDay and Merck.
